New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
1
26

Psoriatic Arthritis. What is psoriatric arthritis? Information | Patient

Synonyms: psoriatic arthropathy, arthropathia psoriatica, arthritis mutilans, seronegative arthritis associated with psoriasis See also separate articles...  
Patient.co.uk
over 5 years ago
Preview
1
23

Gout | Doctor | Patient

Gout can be defined as arthritis due to deposition of monosodium urate (MSU) monohydrate crystals within joints causing acute inflammation and eventual...  
Patient.co.uk
over 5 years ago
Preview
1
26

Calcium Pyrophosphate Deposition - including Pseudogout | Doctor | Patient

Pseudogout is an inflammation of joints caused by the deposition of calcium pyrophosphate (CPP) crystals in articular and periarticular tissues. It is...  
Patient.co.uk
over 5 years ago
Preview
1
34

Reactive Arthritis. Information about Reactive Arthritis | Patient

Reactive Arthritis is also known as Reiter's syndrome. Reactive arthritis is an autoimmune condition that develops in response to an infection.  
Patient.co.uk
over 5 years ago
Preview
1
42

Juvenile Idiopathic Arthritis. JIA information | Patient

Juvenile Idiopathic Arthritis can be known as Still's disease, juvenile arthritis, juvenile chronic arthritis, juvenile rheumatoid arthritis. More about Juvenile Idiopathic Arthritis (JIA)  
Patient.co.uk
over 5 years ago
Www.bmj
1
40

Drug treatments for rheumatoid arthritis: looking backwards to move forwards

Over the past 40 years the clinical picture has improved for patients with rheumatoid arthritis thanks to key steps in drug development and care strategy. These steps include the introduction of methotrexate in 1980 and the first inhibitors of tumour necrosis factor (TNF) in 2000. This was followed by the development of new biotechnology products to target other cytokines, cell subsets, and cell interaction pathways. All these products are expensive drugs with obvious consequences for health systems with limited resources.  
bmj.com
about 5 years ago
Www.bmj
1
11

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

Objective To determine whether intensive combinations of synthetic disease modifying drugs can achieve similar clinical benefits at lower costs to high cost biologics such as tumour necrosis factor inhibitors in patients with active rheumatoid arthritis resistant to initial methotrexate and other synthetic disease modifying drugs.  
bmj.com
about 5 years ago
Www.bmj
1
17

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
bmj.com
about 5 years ago
Www.bmj
1
3

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

Objective To determine whether intensive combinations of synthetic disease modifying drugs can achieve similar clinical benefits at lower costs to high cost biologics such as tumour necrosis factor inhibitors in patients with active rheumatoid arthritis resistant to initial methotrexate and other synthetic disease modifying drugs.  
bmj.com
about 5 years ago
Www.bmj
2
48

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
bmj.com
about 5 years ago
Www.bmj
1
7

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

Objective To determine whether intensive combinations of synthetic disease modifying drugs can achieve similar clinical benefits at lower costs to high cost biologics such as tumour necrosis factor inhibitors in patients with active rheumatoid arthritis resistant to initial methotrexate and other synthetic disease modifying drugs.  
bmj.com
about 5 years ago
Www.bmj
1
13

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
bmj.com
about 5 years ago
Www.bmj
1
10

Drug treatments for rheumatoid arthritis: looking backwards to move forwards

Over the past 40 years the clinical picture has improved for patients with rheumatoid arthritis thanks to key steps in drug development and care strategy. These steps include the introduction of methotrexate in 1980 and the first inhibitors of tumour necrosis factor (TNF) in 2000. This was followed by the development of new biotechnology products to target other cytokines, cell subsets, and cell interaction pathways. All these products are expensive drugs with obvious consequences for health systems with limited resources.  
bmj.com
about 5 years ago
Www.bmj
1
11

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
bmj.com
about 5 years ago
Preview
-1
14

Hands On | Arthritis Research UK

Read previous editions of Hands On, our publication for GPs.  
arthritisresearchuk.org
about 5 years ago
4
0
32

Low WCC in a patient with Rheumatoid Arthritis.

Why would someone with Rheumatoid Arthritis, who is not receiving immunosuppressant medications, have a low White Cell Count?  
Narsene Mahon
over 7 years ago
11
0
24

Why might this patient be feeling nauseous?

A patient feeling excessively nauseous having a history of cholecysectyomy is being administrated with gag's for the treatment of arthritis. The patient complains of vomiting and nausea constantly. Motilium is administrated for nausea but vomiting persist. When lft is done there is a slight increase of bilirubin i.e from 0.2 to 0.3. What is the possible cause of these excessive nauseous feelings? Administration of gag's and chondroiton sulphate or may be due to any problem with the liver function?  
komal zafar
over 7 years ago
4
0
23

What is the first-line therapy for Rheumatoid arthritis?

Hi everyone With so many DMARD's and biologicals available, which one(s) would be first-line therapy for a patient in, say, their forties? (Being 'medically raised' in a resource-limited setting, we don't explore the above options very often.)  
Lize De Klerk
over 7 years ago
0
0
10

What is the disease that decreases pre-existing rheumatoid arthritis?

What is the disease that decreases pre-existing rheumatoid arthritis?  
Rewaa Nasser
over 7 years ago
Www.bmj
0
16

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
feeds.bmj.com
about 5 years ago